Loading...
Targeting opioid dysregulation in depression for the development of novel therapeutics
Since the serendipitous discovery of the first class of modern antidepressants in the 1950’s, all pharmacotherapies approved by the Food and Drug Administration for major depressive disorder (MDD) have shared a common mechanism of action, increased monoaminergic neurotransmission. Despite the widesp...
Na minha lista:
| Udgivet i: | Pharmacol Ther |
|---|---|
| Main Authors: | , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6859062/ https://ncbi.nlm.nih.gov/pubmed/31051197 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.pharmthera.2019.04.009 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|